
Relievant Medsystems Stock
Relievant provides patients with low risk therapy that affords the ability to alleviate their back pain.
Sign up today and learn more about Relievant Medsystems Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Relievant Medsystems Stock
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain.
Funding History
October 2006 | $5.0M |
---|---|
July 2009 | $20.0M |
March 2012 | $30.0M |
February 2015 | $3.0M |
December 2015 | $1.5M |
October 2016 | $36.0M |
June 2018 | $58.0M |
Management
President & CEO
Alex Dinello
Founder & Chief Operating Officer
Rex Peters
Press
bizjournals - Jun, 20 2023
Cigna insures Relievant Medsystems back pain treatmentstartribune - Apr, 20 2023
Relievant Medsystems gets $50M in latest funding roundnews - Apr, 17 2023
Tech Jobs: Here Are 5 Healthtech Startups With Recent Funding Hiring For Multiple Rolesmassdevice - Jan, 3 2022
Relievant Medsystems’ Intracept receives new CPT codes to aid reimbursement effortsglobenewswire - Oct, 2 2021
Relievant Medsystems Announces New Vertebrogenic Low Back Pain ICD-10 Diagnosis Codestartribune - Nov, 9 2020
Bloomington med-tech firm raises $70 million for back pain therapybizjournals - Nov, 6 2020
Relievant Medsystems raises $70M in round led by local investornewswire - Mar, 8 2019
Texas Spine Consultants LLP is First in Texas to Conduct Groundbreaking Intracept Procedurestartribune - Feb, 7 2019
Relievant Medsystems touts strong results from back pain treatment studyprnewswire - Mar, 8 2018
Phoenix Spine Announces Participation in the INTRACEPT Study for the Treatment of Chronic Low Back Painmassdevice - Feb, 14 2018
Relievant touts 1-year Intracept trial resultsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase